Bixlenvo offers a simplified option for patients whose HIV is under control but who can’t use current single-pill treatments.

A new once-weekly HIV pill matched daily treatment in a Phase 3 trial, offering a potentially simpler option for people with ...

​More than 83% of people receiving HIV care are on continuous antiretroviral treatment in the country, and have achieved ...

The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including ...

As the first second-generation INSTI approved for newborns with HIV, this approval allows for a simpler, more robust antiretroviral therapy regimen than existing standard of care.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new sequential immunization strategy shows strong promise for an HIV vaccine, a ...

An infectious disease specialist discusses HIV prevention barriers facing Black women and how long-acting options and ...

HIV doesn’t discriminate, but societal barriers have left Black Americans disproportionately affected. HIV prevention options could help.

Uninterrupted access to HIV treatment suppresses the virus to undetectable levels, protecting the immune system and stopping ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3% in ...

Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to ...

In the early decades of the global response to HIV/AIDS, the focus was on saving lives. And rightly so: without antiretroviral treatment (ART), people lived less than a year, on average, from the time ...